Marković, F.; Milin-Lazović, J.; Nikolić, N.; Golubović, A.; Stjepanović, M.; Kontić, M.
KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis. Curr. Oncol. 2025, 32, 365.
https://doi.org/10.3390/curroncol32060365
AMA Style
Marković F, Milin-Lazović J, Nikolić N, Golubović A, Stjepanović M, Kontić M.
KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis. Current Oncology. 2025; 32(6):365.
https://doi.org/10.3390/curroncol32060365
Chicago/Turabian Style
Marković, Filip, Jelena Milin-Lazović, Nikola Nikolić, Aleksa Golubović, Mihailo Stjepanović, and Milica Kontić.
2025. "KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis" Current Oncology 32, no. 6: 365.
https://doi.org/10.3390/curroncol32060365
APA Style
Marković, F., Milin-Lazović, J., Nikolić, N., Golubović, A., Stjepanović, M., & Kontić, M.
(2025). KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis. Current Oncology, 32(6), 365.
https://doi.org/10.3390/curroncol32060365
